BioNTech Signs Rare Disease Co-Development Deal With Genevant & Licenses LNP Platform

BioNTech and Genevant have boosted their clinical ambitions by agreeing a 50/50 co-development, co-commercialization collaboration for five mRNA rare disease programs. BioNTech also secured exclusive licenses to Genevant's LNP drug delivery platform for five oncology programs.

business

BioNTech AG, Europe’s largest privately held biotech, has signed two deals with Genevant Sciences Ltd., a joint venture created earlier this year by Vancouver-based Arbutus Biopharma Corp. and Roivant Sciences GMBH, which are expected to support the clinical ambitions of both companies.

In the first deal, the companies have agreed to combine Genevant’s lipid nanoparticle (LNP) drug delivery technology with BioNTech’s mRNA...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immuno-oncology

More from Anticancer